Bausch + Lomb Corporation BLCO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About BLCO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Bausch + Lomb Corporation is a global eye health company focused on vision care, ophthalmic pharmaceuticals, surgical products, and consumer eye health solutions. The company operates across the broader healthcare and medical technology industries, serving patients, eye care professionals, hospitals, ambulatory surgery centers, and retail consumers. Its primary revenue drivers include contact lenses, lens care products, prescription ophthalmic medicines, over-the-counter eye care products, cataract surgery equipment, and vitreoretinal surgical systems. The company competes with other major ophthalmology and vision care firms through a diversified product portfolio spanning both medical devices and pharmaceuticals.
The company traces its origins to 1853 when it was founded in Rochester, New York by John Jacob Bausch and Henry Lomb. Over time, it evolved from an optical goods manufacturer into a diversified eye health company with global operations. Bausch + Lomb underwent multiple ownership changes, including acquisition by Valeant Pharmaceuticals (later renamed Bausch Health Companies). In 2022, Bausch + Lomb Corporation returned to the public markets through an initial public offering while maintaining operational ties to Bausch Health. The company positions itself through broad product diversification, established ophthalmology relationships, a large international distribution footprint, and a recognized brand in eye care supported by product development and regulatory expertise.
Business Operations
Bausch + Lomb organizes its operations primarily across three business segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes contact lenses, lens care solutions, and eye vitamins, with products sold through eye care professionals, retailers, and distributors. The Pharmaceuticals segment includes branded prescription therapies, generic ophthalmic medicines, and over-the-counter eye health products addressing conditions such as dry eye, glaucoma, ocular inflammation, and allergies. The Surgical segment provides equipment and consumables used in cataract and vitreoretinal surgery, including intraocular lenses, phacoemulsification systems, and surgical instruments. Revenue is generated through product sales across healthcare providers, pharmacies, optical retail channels, and hospital systems.
The company maintains manufacturing, research, and commercial operations across North America, Europe, Asia-Pacific, and Latin America. Bausch + Lomb controls a portfolio of ophthalmic technologies, intellectual property, and manufacturing assets supporting both pharmaceuticals and medical devices. Major subsidiaries and operational entities include Bausch + Lomb Americas Inc. and regional operating affiliates across Europe and Asia. The company has also maintained commercial and development partnerships related to ophthalmic therapies and medical technologies. Public filings and investor materials identify ongoing investments in product innovation, manufacturing capacity, and digital eye health capabilities.
Strategic Position & Investments
Bausch + Lomb’s strategic direction centers on expanding its global eye health platform through product innovation, geographic expansion, and targeted acquisitions. The company has emphasized growth in premium contact lenses, dry eye treatments, surgical technologies, and ophthalmic pharmaceuticals. Strategic initiatives highlighted in public filings include expanding silicone hydrogel contact lens adoption, strengthening cataract surgery offerings, and advancing pharmaceutical pipelines for retinal and ocular surface diseases. The company also continues investing in research and development capabilities to support long-term growth across both devices and therapeutics.
Recent investments and acquisitions include the acquisition of XIIDRA from Novartis, which strengthened Bausch + Lomb’s position in prescription dry eye treatment. The company has also invested in manufacturing modernization and surgical product development. Its portfolio includes recognized brands such as Biotrue, ULTRA, PureVision, and Lumify. Emerging focus areas include digital ophthalmology technologies, advanced intraocular lenses, preservative-free eye care formulations, and expanded ophthalmic drug delivery systems. While the company continues to evaluate additional strategic transactions and pipeline opportunities, publicly available disclosures do not confirm all prospective initiatives; therefore, some future investment plans remain subject to regulatory filings and market conditions.
Geographic Footprint
Bausch + Lomb operates in more than 100 countries with corporate headquarters in Vaughan, Ontario, Canada. The company maintains significant operational and commercial presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The United States represents a major revenue market, supported by broad distribution across retail optical, pharmaceutical, and surgical channels. International markets contribute a substantial portion of overall revenue through both developed and emerging healthcare systems.
The company’s global footprint includes manufacturing facilities, research centers, and commercial offices distributed across multiple continents. Bausch + Lomb maintains particularly strong market positions in ophthalmic pharmaceuticals and contact lens products in regions including Europe, China, Japan, and Latin America. Its international operational influence is supported by long-standing relationships with ophthalmologists, optometrists, distributors, hospitals, and healthcare providers worldwide. Public disclosures also indicate ongoing investment in regional manufacturing and supply chain diversification to support global demand and regulatory compliance.
Leadership & Governance
Bausch + Lomb’s leadership structure combines executives with backgrounds in pharmaceuticals, medical devices, consumer healthcare, and global operations. The company emphasizes long-term growth in eye health through innovation, commercial execution, operational efficiency, and expansion across both developed and emerging markets. Governance practices are guided by public company reporting standards and oversight structures outlined in SEC filings, including annual reports and proxy statements. Strategic messaging from management has consistently focused on building a pure-play global eye health platform with diversified revenue streams.
Key executives include:
- Brent Saunders – Executive Chair and Chief Executive Officer
- Sam Eldessouky – Chief Financial Officer
- Yehia Hashad, MD – Executive Vice President, Research & Development and Chief Medical Officer
- Luc Bonnefoy – President, Global Pharmaceuticals and International Consumer
- Anthony Wallace – President, Global Vision Care
- John Ferris – President, Global Surgical
- Andrew Stewart – Executive Vice President, General Counsel and Corporate Secretary
The company’s governance and leadership information has been verified through publicly available SEC filings, company investor relations materials, major financial publications, and market disclosures available as of recent reporting periods. Where leadership roles or strategic initiatives may change over time, investors should refer to the most recent regulatory filings for confirmation.